LHI’s performance on the Anthrax Vaccination Program (AVP) led to the addition of the Anthrax Vaccination Program Observational Sub-studies in October of 2002.
The AVP offered a unique opportunity for the CDC to study the safety and tolerability of the anthrax vaccine in a civilian population. The CDC added a total of three studies that were performed by LHI in conjunction with the AVP. These three safety studies included an evaluation of the factors that influence a person’s decision to accept or reject AVA vaccinations, an evaluation of whether AVA impacts health related quality of life, and an evaluation of the possible associations between sex hormones levels and the occurrence of local adverse events (AEs).
The implementation of the sub-studies required LHI to meet program goals by effectively recruiting study participants, training and recruiting providers, administering survey instruments, and collecting and recording data.